Merck & Co., Inc. (MRK) Current Ratio: 1.54
Is Merck & Co., Inc.’s current ratio high or low?
Merck & Co., Inc.'s current ratio of 1.54 is 17% above its 5-year average of 1.32, near the high end of its 5-year range (1.02–1.54).
The current ratio for Merck & Co., Inc. (MRK) is 1.54 as of Tuesday, June 9, 2026. It is above its 12-month average by 6.21% (1.45).
MRK Current Ratio Chart
MRK Average Current Ratio Chart
MRK Current vs Average Current Ratio Chart
MRK Current Ratio Metrics
CURRENT RATIO
1.54
CURRENT RATIO AVG TTM
1.45
CURRENT RATIO AVG 3Y
1.41
CURRENT RATIO AVG 5Y
1.32
CURRENT RATIO AVG 10Y
1.36
CURRENT RATIO AVG 15Y
1.53
CURRENT RATIO AVG 20Y
1.51
CURRENT VS TTM AVG
+6.21%
CURRENT VS 3Y AVG
+9.61%
CURRENT VS 5Y AVG
+16.81%
CURRENT VS 10Y AVG
+13.08%
CURRENT VS 15Y AVG
+0.37%
CURRENT VS 20Y AVG
+1.95%
MRK Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | — | 1.54 | 1.45 | 1.41 | 1.32 |
| UnitedHealth Group Incorporated (UNH) | $375.06B | 0.79 | 0.81 | 0.80 | 0.79 |
| AbbVie Inc. (ABBV) | $398.27B | 0.67 | 0.67 | 0.79 | 0.80 |
| Amgen Inc. (AMGN) | $185.96B | 1.14 | 1.20 | 1.36 | 1.48 |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 1.89 | 1.77 | 1.69 | 1.74 |
| Abbott Laboratories (ABT) | $158.94B | 1.58 | 1.63 | 1.63 | 1.68 |
| Gilead Sciences, Inc. (GILD) | $155.82B | 1.68 | 1.64 | 1.50 | 1.45 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 4.87 | 4.47 | 4.53 | 5.01 |
| Pfizer Inc. (PFE) | $146.48B | 1.16 | 1.17 | 1.11 | 1.20 |
| Danaher Corporation (DHR) | $133.37B | 1.87 | 1.64 | 1.71 | 1.69 |
Liquidity Analysis
Current Ratio
1.54
Quick Ratio
1.30
Merck & Co., Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Current Ratio FAQ
- What is the current ratio for Merck & Co., Inc. (MRK)?
- The current ratio for MRK stock is 1.54.
- Is Merck & Co., Inc.'s current ratio high or low?
- Merck & Co., Inc.'s current ratio of 1.54 is 17% above its 5-year average of 1.32, near the high end of its 5-year range (1.02–1.54).
- What is the TTM average current ratio for Merck & Co., Inc. (MRK)?
- The TTM average current ratio for MRK stock is 1.45.
- What is the 3Y average current ratio for Merck & Co., Inc. (MRK)?
- The 3Y average current ratio for MRK stock is 1.41.
- What is the 5Y average current ratio for Merck & Co., Inc. (MRK)?
- The 5Y average current ratio for MRK stock is 1.32.
- What is the 10Y average current ratio for Merck & Co., Inc. (MRK)?
- The 10Y average current ratio for MRK stock is 1.36.
- What is the 15Y average current ratio for Merck & Co., Inc. (MRK)?
- The 15Y average current ratio for MRK stock is 1.53.
- What is the 20Y average current ratio for Merck & Co., Inc. (MRK)?
- The 20Y average current ratio for MRK stock is 1.51.
Merck & Co., Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 1.54 |
| 2024-12-31 | 1.36 |
| 2023-12-31 | 1.25 |
| 2022-12-31 | 1.47 |
| 2021-12-31 | 1.27 |
| 2020-12-31 | 1.02 |
| 2019-12-31 | 1.24 |
| 2018-12-31 | 1.17 |
| 2017-12-31 | 1.33 |
| 2016-12-31 | 1.78 |
| 2015-12-31 | 1.55 |
| 2014-12-31 | 1.77 |
| 2013-12-31 | 2.00 |
| 2012-12-31 | 1.90 |
| 2011-12-31 | 2.04 |
| 2010-12-31 | 1.86 |
| 2009-12-31 | 1.82 |
| 2008-12-31 | 1.33 |
| 2007-12-31 | 1.23 |
| 2006-12-31 | 1.20 |
| 2005-12-31 | 1.59 |
| 2004-12-31 | 1.15 |
| 2003-12-31 | 1.20 |
| 2002-12-31 | 1.16 |
| 2001-12-31 | 1.12 |
| 2000-12-31 | 1.38 |
| 1999-12-31 | 1.29 |
| 1998-12-31 | 1.69 |
| 1997-12-31 | 1.47 |
| 1996-12-31 | 1.60 |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis